Close Menu

NEW YORK (GenomeWeb) – Meridian Bioscience announced today that its preliminary fiscal second quarter revenues are expected to be down nearly 12 percent year over year driven by a decline in revenues in its diagnostics segment.

For fiscal Q2 2019, the company said that revenues are anticipated to be approximately $50.0 million compared to $56.5 million a year ago. The analysts' average estimate is $56.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.